No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of various pharmaceutical products in China and internationally. The company provides Chinese medicine formula granules, finished drugs, raw materials, medical devices and excipients, medical and health services, as well as smart supply chain for pharmaceuticals and medical devices. It serves the fields of immunity, cardiovascular and cerebrovascular diseases, respiratory system, and neurodegenerative diseases. The company was founded in 1996 and is headquartered in Tianjin, China.
www.chasesun.cnNo one on the platform currently holds 300026.SZ.
No tracked institution reports a position in 300026.SZ as of their last filing.
No one on the platform has traded 300026.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 0.5% | — | — | — | ||
| Rev. Growth % | -15.2% | -5.5% | ||||
| Profit Margin % | 0.4% | 5.5% | 8.0% | |||
| Free Cash Flow Margin % | 13.9% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $7.1B | +8.8% | $0.22 | $0.22–$0.22 | — | 1 |
| 2027 | $5.6B | -20.3% | $0.15 | $0.15–$0.15 | — | 1 |
| 2028 | $6.3B | +12.3% | $0.20 | $0.20–$0.20 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300026.SZTianjin Chase Sun Pharmaceutical Co., Ltd. Class A | $3.19 | +0.31% | $9.6B | — |
| 002550.SZChangzhou Qianhong Biopharma CO.,LTD | $6.31 | -0.00% | $7.7B | — |
| 002626.SZXiamen Kingdomway Group Company | $16.26 | +0.74% | $9.9B | — |
| 600129.SSChongqing Taiji Industry(Group) Co.,Ltd | $13.37 | -0.30% | $7.4B | — |
| 600285.SSHenan Lingrui Pharmaceutical Co., Ltd. |
| $19.12 |
| -0.78% |
| $10.8B |
| — |
| 600422.SSKPC Pharmaceuticals, Inc. | $8.12 | -0.61% | $6.1B | — |
| 600812.SSNorth China Pharmaceutical Company Ltd. | $4.55 | -0.87% | $7.8B | — |
Source: Financial Modeling Prep · peers by sector/industry